Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach.
Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M, Rübenacker L, Grüttner C, Garcia MG; MVA-MERS-S-CEF study group; Koch T, Becker S, Sutter G, Lhomme E, Haagmans BL, Fathi A, Blois SM, Dahlke C, Richert L, Addo MM. Weskamm LM, et al. Among authors: friedrich m. iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. eCollection 2024 Aug 16. iScience. 2024. PMID: 39148710 Free PMC article.
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome.
Fathi A, Dahlke C, Krähling V, Kupke A, Okba NMA, Raadsen MP, Heidepriem J, Müller MA, Paris G, Lassen S, Klüver M, Volz A, Koch T, Ly ML, Friedrich M, Fux R, Tscherne A, Kalodimou G, Schmiedel S, Corman VM, Hesterkamp T, Drosten C, Loeffler FF, Haagmans BL, Sutter G, Becker S, Addo MM. Fathi A, et al. Among authors: friedrich m. Nat Commun. 2022 Jul 19;13(1):4182. doi: 10.1038/s41467-022-31557-0. Nat Commun. 2022. PMID: 35853863 Free PMC article.
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM. Mayer L, et al. Among authors: friedrich m. NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. NPJ Vaccines. 2024. PMID: 38278816 Free PMC article.
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423-7. doi: 10.1016/S1473-3099(24)00423-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389076
MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.
Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krähling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. Grewe I, et al. Among authors: friedrich m. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024. Front Immunol. 2024. PMID: 39749328 Free PMC article. Clinical Trial.
Rational engineering of minimally immunogenic nucleases for gene therapy.
Raghavan R, Friedrich MJ, King I, Chau-Duy-Tam Vo S, Strebinger D, Lash B, Kilian M, Platten M, Macrae RK, Song Y, Nivon L, Zhang F. Raghavan R, et al. Among authors: friedrich mj. Nat Commun. 2025 Jan 2;16(1):105. doi: 10.1038/s41467-024-55522-1. Nat Commun. 2025. PMID: 39747875 Free PMC article.
1,974 results